Literature DB >> 22675273

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Douglas G Altman1, Lisa M McShane, Willi Sauerbrei, Sheila E Taube.   

Abstract

The REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guideline includes a checklist which aims to improve the reporting of these types of studies. Here, we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report. Each checklist item of the REMARK guideline is explained in detail and accompanied by published examples of good reporting. The paper provides a comprehensive overview to educate on good reporting and provide a valuable reference of issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22675273      PMCID: PMC3362085          DOI: 10.1371/journal.pmed.1001216

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


  180 in total

1.  Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival.

Authors:  Dirk Watermann; Helmut Madjar; Willi Sauerbrei; Valerie Hirt; Heinrich Prömpeler; Elmar Stickeler
Journal:  Oncol Rep       Date:  2004-04       Impact factor: 3.906

Review 2.  Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies.

Authors:  Willi Sauerbrei
Journal:  Adv Otorhinolaryngol       Date:  2005

3.  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Authors:  George Pentheroudakis; Konstantine T Kalogeras; Ralph M Wirtz; Irene Grimani; George Zografos; Helen Gogas; Udo Stropp; Dimitrios Pectasides; Dimosthenis Skarlos; Guido Hennig; Epaminondas Samantas; Dimitrios Bafaloukos; Pavlos Papakostas; Haralabos P Kalofonos; Nicholas Pavlidis; George Fountzilas
Journal:  Breast Cancer Res Treat       Date:  2008-07-31       Impact factor: 4.872

4.  Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers.

Authors:  I de Mascarel; F Bonichon; M Durand; L Mauriac; G MacGrogan; I Soubeyran; V Picot; A Avril; J M Coindre; M Trojani
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

5.  p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.

Authors:  Monica M Bertagnolli; Robert S Warren; Donna Niedzwiecki; Elke Mueller; Carolyn C Compton; Mark Redston; Margaret Hall; Hejin P Hahn; Scott D Jewell; Robert J Mayer; Richard M Goldberg; Leonard B Saltz; Massimo Loda
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.

Authors:  Gertraud Stocker; Katja Ott; Nils Henningsen; Karen Becker; Alexander Hapfelmeier; Florian Lordick; Stefan Hois; Susanne Plaschke; Heinz Höfler; Gisela Keller
Journal:  Eur J Cancer       Date:  2009-10-12       Impact factor: 9.162

7.  Neutral endopeptidase protein expression and prognosis in localized prostate cancer.

Authors:  Iman Osman; Herman Yee; Samir S Taneja; Benjamin Levinson; Anne Zeleniuch-Jacquotte; Caroline Chang; Craig Nobert; David M Nanus
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

8.  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.

Authors:  D Loussouarn; L Campion; F Leclair; M Campone; C Charbonnel; G Ricolleau; W Gouraud; R Bataille; P Jézéquel
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

9.  Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Authors:  Yi Yan; George P Skliris; Carla Penner; Shilpa Chooniedass-Kothari; Charlton Cooper; Zoann Nugent; Anne Blanchard; Peter H Watson; Yvonne Myal; Leigh C Murphy; Etienne Leygue
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

Review 10.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  315 in total

Review 1.  A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.

Authors:  Reema Mallick; Santosh K Patnaik; Sachin Wani; Ajay Bansal
Journal:  Dig Dis Sci       Date:  2015-11-14       Impact factor: 3.199

2.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

3.  A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Authors:  Elena Martínez-Terroba; Carmen Behrens; Fernando J de Miguel; Jackeline Agorreta; Eduard Monsó; Laura Millares; Cristina Sainz; Miguel Mesa-Guzman; José Luis Pérez-Gracia; María Dolores Lozano; Javier J Zulueta; Ruben Pio; Ignacio I Wistuba; Luis M Montuenga; María J Pajares
Journal:  J Pathol       Date:  2018-06-20       Impact factor: 7.996

4.  Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.

Authors:  Ran Tao; Qiang Li; Xiaofei Gao; Lilin Ma
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

5.  Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

Authors:  George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2014-04-19       Impact factor: 6.603

6.  Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Authors:  James N Ingle; Fang Xie; Matthew J Ellis; Paul E Goss; Lois E Shepherd; Judith-Anne W Chapman; Bingshu E Chen; Michiaki Kubo; Yoichi Furukawa; Yukihide Momozawa; Vered Stearns; Kathleen I Pritchard; Poulami Barman; Erin E Carlson; Matthew P Goetz; Richard M Weinshilboum; Krishna R Kalari; Liewei Wang
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

Review 7.  From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers.

Authors:  Anudeep Yekula; Koushik Muralidharan; Keiko M Kang; Lan Wang; Leonora Balaj; Bob S Carter
Journal:  Methods       Date:  2020-02-12       Impact factor: 3.608

8.  Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.

Authors:  James N Ingle; Junmei Cairns; Vera J Suman; Lois E Shepherd; Peter A Fasching; Tanya L Hoskin; Ravinder J Singh; Zeruesenay Desta; Krishna R Kalari; Matthew J Ellis; Paul E Goss; Bingshu E Chen; Bernhard Volz; Poulami Barman; Erin E Carlson; Tufia Haddad; Matthew P Goetz; Barbara Goodnature; Matthew E Cuellar; Michael A Walters; Cristina Correia; Scott H Kaufmann; Richard M Weinshilboum; Liewei Wang
Journal:  Clin Cancer Res       Date:  2020-02-25       Impact factor: 12.531

Review 9.  Biomarkers in reproductive medicine: the promise, and can it be fulfilled?

Authors:  Stephen S Palmer; Kurt T Barnhart
Journal:  Fertil Steril       Date:  2012-12-14       Impact factor: 7.329

Review 10.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.